Tag: Intensive Care Conference
– Multiple Unyvero product launches planned for 2015
– Clinical trial aimed at US FDA clearance of Unyvero adapted to reflect most recent FDA guideline issued in Q3-2014
Curetis AG, a developer of next-level molecular diagnostic solutions, today announced the presentation of its product range at Germany’s biggest congress on intensive medicine and intensive care, Symposium Intensivmedizin + Intensivpflege, in Bremen from February 18-20, 2015. Curetis will be exhibiting the Unyvero Solution at booth #N27, hall 4 at Messe & Congress Centrum Bremen. Curetis is also providing an update on its pipeline of new products to be launched in 2015.
By the end of 2014, the installed base of Curetis´ Unyvero Solution has grown to more than 60 systems world-wide. Unyvero is a versatile hardware platform for the detection of a broad panel of bacteria, fungi and antibiotic resistances from a single sample in one run. At present, cartridges for pneumonia testing (Unyvero P50) and for implant & tissue infections (Unyvero i60 ITI) are available in Europe. The company is expecting the European launch of its enhanced and expanded Unyvero P55 Pneumonia application in the spring of 2015.
By mid 2015, Curetis also anticipates data from an updated i60 ITI application Cartridge. Moreover, the company is planning the launch of a comprehensive blood culture panel combining Gram-positive and Gram-negative pathogen markers as well as resistance markers by the end of 2015 in Europe.
The company also announced an update on its US trial of the Unyvero LRT lower respiratory tract infection application. Curetis has adapted its FDA trial design to reflect the new guidelines issued by the FDA for multiplexed infectious diseases tests and will re-initiate prospective sample measurement once the enhanced and expanded P55 Pneumonia Cartridge is available as LRT-labeled test cartridges for the US FDA trial. Patient sample collection with the updated LRT application based on the P55 assay is expected to start mid-2015.
Curetis has decided to un-blind all data generated in its FDA trial to date and has engaged its network of US trial sites to continue collecting retrospective specimen. Data from the previous LRT study based on the P50 panel will be analyzed and published in a peer-reviewed format.
The new FDA guideline reduces the minimum number of required prospective patient samples to 1,500, limits requirements for prospective samples to only specificity endpoints, allows testing of retrospectively collected patient samples for sensitivity endpoints, and provides clarity on positive and negative control samples. Based on the adapted design and a start of patient sample collection with the new LRT55 application, which is anticipated by mid-2015, Curetis is expecting completion of patient enrolment in the first half of 2016, with subsequent filing with the FDA.